Idiopathic Pulmonary Fibrosis
"Idiopathic Pulmonary Fibrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.
| Descriptor ID |
D054990
|
| MeSH Number(s) |
C08.381.483.487.500 C08.381.765.500
|
| Concept/Terms |
Idiopathic Pulmonary Fibrosis- Idiopathic Pulmonary Fibrosis
- Idiopathic Pulmonary Fibroses
- Pulmonary Fibroses, Idiopathic
- Familial Idiopathic Pulmonary Fibrosis
- Fibrocystic Pulmonary Dysplasia
- Dysplasia, Fibrocystic Pulmonary
- Dysplasias, Fibrocystic Pulmonary
- Fibrocystic Pulmonary Dysplasias
- Pulmonary Dysplasia, Fibrocystic
- Pulmonary Dysplasias, Fibrocystic
- Fibrosing Alveolitis, Cryptogenic
- Hamman-Rich Disease
- Disease, Hamman-Rich
- Diseases, Hamman-Rich
- Hamman Rich Disease
- Hamman-Rich Diseases
- Interstitial Pneumonitis, Usual
- Interstitial Pneumonitides, Usual
- Pneumonitides, Usual Interstitial
- Pneumonitis, Usual Interstitial
- Usual Interstitial Pneumonitides
- Usual Interstitial Pneumonitis
- Pulmonary Fibrosis, Idiopathic
- Usual Interstitial Pneumonia
- Interstitial Pneumonia, Usual
- Interstitial Pneumonias, Usual
- Usual Interstitial Pneumonias
- Idiopathic Fibrosing Alveolitis, Chronic Form
- Cryptogenic Fibrosing Alveolitis
- Cryptogenic Fibrosing Alveolitides
- Fibrosing Alveolitides, Cryptogenic
- Idiopathic Pulmonary Fibrosis, Familial
|
Below are MeSH descriptors whose meaning is more general than "Idiopathic Pulmonary Fibrosis".
Below are MeSH descriptors whose meaning is more specific than "Idiopathic Pulmonary Fibrosis".
This graph shows the total number of publications written about "Idiopathic Pulmonary Fibrosis" by people in this website by year, and whether "Idiopathic Pulmonary Fibrosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 2 | 0 | 2 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 0 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 4 | 0 | 4 |
| 2014 | 6 | 0 | 6 |
| 2015 | 2 | 0 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 5 | 0 | 5 |
| 2019 | 6 | 2 | 8 |
| 2020 | 6 | 1 | 7 |
| 2021 | 2 | 0 | 2 |
| 2022 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Idiopathic Pulmonary Fibrosis" by people in Profiles.
-
Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Ann Am Thorac Soc. 2022 06; 19(6):981-990.
-
Three-Month FVC Change: A Trial Endpoint for Idiopathic Pulmonary Fibrosis Based on Individual Participant Data Meta-analysis. Am J Respir Crit Care Med. 2022 04 15; 205(8):936-948.
-
Lung transplantation for idiopathic pulmonary fibrosis enriches for individuals with telomere-mediated disease. J Heart Lung Transplant. 2022 05; 41(5):654-663.
-
Dysfunctional lactate metabolism in human alveolar type II cells from idiopathic pulmonary fibrosis lung explant tissue. Respir Res. 2021 Oct 28; 22(1):278.
-
TL1A Promotes Lung Tissue Fibrosis and Airway Remodeling. J Immunol. 2020 11 01; 205(9):2414-2422.
-
Pulmonary fibrosis: something old, something new?still waiting for a breakthrough. Am J Physiol Lung Cell Mol Physiol. 2020 09 01; 319(3):L560-L561.
-
CD70 Activation Decreases Pulmonary Fibroblast Production of Extracellular Matrix Proteins. Am J Respir Cell Mol Biol. 2020 08; 63(2):255-265.
-
Response to: letter to the editor: consideration on 'an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and drug administration and the European medicines agency' by bennett et al. Expert Opin Drug Saf. 2020 08; 19(8):1057-1058.
-
Prominence of IL6, IGF, TLR, and Bioenergetics Pathway Perturbation in Lung Tissues of Scleroderma Patients With Pulmonary Fibrosis. Front Immunol. 2020; 11:383.
-
Cross-Talk between Transforming Growth Factor-? and Periostin Can Be Targeted for Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2020 02; 62(2):204-216.